Skip to main content
Caplight Logo









ORCA Therapeutics

ORCA Therapeutics

Private
NijmegenHealthcare & Life Scienceshttps://www.orca-therapeutics.nl/

Last Round

VC Round

Sep 23, 2024

Total Funding Raised

$2.73M

Company Overview

ORCA Therapeutics is a biopharmaceutical company that develops oncolytic virus immunotherapies designed to selectively kill cancer cells and induce an antitumor immune response for cancers such as prostate cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

oncolytic immunotherapyoncolytic viruscancer immunotherapyadenovirussolid tumor treatmentbiotechnologyviral therapyclinical-stage biotechdrug developmentcancer researchbiopharmaoncolytic virotherapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ORCA Therapeutics Comparables

Compare ORCA Therapeutics with similar companies based on industry and business-model similarity.

ORCA Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Lokon Pharma
85%
TILT Biotherapeutics
84%
Theolytics
83%

ORCA Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundSep 23, 2024
GrantMay 4, 2016
VC RoundApr 1, 2016
DebtNov 8, 2011

Key People

Founding team and executive leadership

Wenliang Dong

Chief Executive Officer

Executive Team

ORCA Therapeutics Investors

Notable investors and investment history

ORCA Therapeutics investors
InvestorRounds
European CommissionGrant
Oost NLVC Round
Aglaia Oncology FundsVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 23, 2024

    $2.2M round led by Aglaia Oncology Funds and Oost NL.

  • May 4, 2016

    Secured $1.27M from the European Commission and Horizon 2020.

ORCA Therapeutics Filings

Explore SEC and related filing metadata, where available.

ORCA Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about ORCA Therapeutics's valuation, stock price, and market status.

Is ORCA Therapeutics a public or private company?

ORCA Therapeutics is a private company.

What is the current stock price of ORCA Therapeutics?

ORCA Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is ORCA Therapeutics worth (valuation)?

Valuation information for ORCA Therapeutics is not publicly available.

Can I buy ORCA Therapeutics stock?

ORCA Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was ORCA Therapeutics's last funding round?

ORCA Therapeutics's most recent funding round was VC Round on September 23, 2024.

Who are the main investors in ORCA Therapeutics?

Key investors in ORCA Therapeutics include European Commission.

Will ORCA Therapeutics IPO soon?

No public IPO plans have been announced for ORCA Therapeutics.

How can I track ORCA Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ORCA Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNijmegen
Employee Range6
Year Founded2005
Last FundingSep 23, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?